Centaurus Financial’s PDL BioPharma, Inc. PDLI Stock Holding History

Centaurus Financial’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-57	Closed	–	–	2471
2018 Q2	$0	Buy	+57	New	+$159	﹤0.01%	2502

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Centaurus Financial's PDLI Position: Q3 2018 in Review

Centaurus Financial sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 57 shares.

Centaurus Financial first reported a position in PDLI in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Centaurus Financial reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 57 PDL BioPharma, Inc. shares in Q3 2018.
Centaurus Financial first reported a position in PDL BioPharma, Inc. in Q2 2018 and held it in 1 quarter.
Centaurus Financial's PDL BioPharma, Inc. position peaked at $0 in Q2 2018.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.